Latigo Biotherapeutics has administered the first dose to a participant in its Phase 1 clinical trial for LTG-305, aimed at non-opioid pain management.

IgGenix has reported that the initial patient has been dosed in its Phase 1 trial, named "ACCELERATE Peanut," which is testing IGNX001 for peanut allergies.

Innovent has revealed that its Phase 2 clinical trial of Picankibart (IBI112) in Chinese patients with ulcerative colitis has met its primary goal.

Alnylam has filed a regulatory application with the European Medicines Agency for Vutrisiran aimed at treating ATTR amyloidosis with cardiomyopathy.

SciRhom GmbH has announced the initiation of participant dosing in their first clinical trial for the advanced development program SR-878.

UroGen Pharma announced the acceptance of its NDA by the U.S. FDA for the investigational product UGN-102 (mitomycin) intended for intravesical administration.

Adicet Bio has received FDA approval for an IND amendment to study ADI-001 in idiopathic inflammatory myopathy and Stiff Person Syndrome.

ViiV Healthcare reports over 99% effectiveness for Apretude (Cabotegravir Long-Acting) in real-world studies.

Sanofi has partnered with Orano Med, a branch of the Orano Group that leads in the advancement of targeted alpha therapies for cancer treatment.

uniQure N.V. has announced that the initial participant has received a dose in the Phase I/II clinical study of AMT-162.

Three novel drugs by Gan & Lee Pharmaceuticals-GZR18, GZR4, and GZR101 injections-meet primary goals in Phase 2 trials.

Amgen reveals favorable Phase 3 results for Uplizna® (inebilizumab-cdon) in treating generalized myasthenia gravis at AANEM 2024.